Literature DB >> 9323565

The association between haematological manifestation and mtDNA deletions in Pearson syndrome.

K Muraki1, S Nishimura, Y Goto, I Nonaka, N Sakura, K Ueda.   

Abstract

We studied the proportion of deleted mitochondrial DNA in blood cells from patients with Pearson syndrome. Patient 1 is a 17-year-old female with Kearns-Sayre syndrome who survived Pearson syndrome. Patient 2 is a 5-year-old boy with Pearson syndrome who recovered from refractory anaemia but continues to have thrombocytopenia and neutropenia. Patient 3 is a female neonate who died with severe acidosis and pancytopenia at 14 days of age. Southern blot analysis was performed with total DNA from three patients' blood cells and two samples of bone marrow cells from one patient. In peripheral blood, patients with a higher proportion of deleted mitochondrial DNA had lower blood cell counts. In patient 2, the percentage of mutant mitochondrial DNA in bone marrow cells decreased as anaemia improved. This indicates that the proportion of deleted mitochondrial DNA in peripheral blood and in bone marrow has a tendency to correlate to the severity of haematological manifestation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9323565     DOI: 10.1023/a:1005378527077

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  13 in total

1.  Progressive increase of the mutated mitochondrial DNA fraction in Kearns-Sayre syndrome.

Authors:  N G Larsson; E Holme; B Kristiansson; A Oldfors; M Tulinius
Journal:  Pediatr Res       Date:  1990-08       Impact factor: 3.756

2.  Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction.

Authors:  J Hayashi; S Ohta; A Kikuchi; M Takemitsu; Y Goto; I Nonaka
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Sequence and organization of the human mitochondrial genome.

Authors:  S Anderson; A T Bankier; B G Barrell; M H de Bruijn; A R Coulson; J Drouin; I C Eperon; D P Nierlich; B A Roe; F Sanger; P H Schreier; A J Smith; R Staden; I G Young
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

4.  Severe lactic acidosis and neonatal death in Pearson syndrome.

Authors:  K Muraki; Y Goto; I Nishino; M Hayashidani; S Takeuchi; S Horai; N Sakura; K Ueda
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

5.  Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome.

Authors:  C T Moraes; S DiMauro; M Zeviani; A Lombes; S Shanske; A F Miranda; H Nakase; E Bonilla; L C Werneck; S Servidei
Journal:  N Engl J Med       Date:  1989-05-18       Impact factor: 91.245

6.  Molecular and genetic analyses of two patients with Pearson's marrow-pancreas syndrome.

Authors:  T Sano; K Ban; T Ichiki; M Kobayashi; M Tanaka; K Ohno; T Ozawa
Journal:  Pediatr Res       Date:  1993-07       Impact factor: 3.756

7.  Kearns-Sayre's syndrome developing in a boy who survived pearson's syndrome caused by mitochondrial DNA deletion.

Authors:  H J Simonsz; K Bärlocher; A Rötig
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

8.  Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome.

Authors:  A Rötig; T Bourgeron; D Chretien; P Rustin; A Munnich
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

9.  Are duplications of mitochondrial DNA characteristic of Kearns-Sayre syndrome?

Authors:  J Poulton; K J Morten; K Weber; G K Brown; L Bindoff
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

10.  A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction.

Authors:  H A Pearson; J S Lobel; S A Kocoshis; J L Naiman; J Windmiller; A T Lammi; R Hoffman; J C Marsh
Journal:  J Pediatr       Date:  1979-12       Impact factor: 4.406

View more
  8 in total

1.  Hematopoiesis in the thymidine kinase 2 deficient mouse model of mitochondrial DNA depletion syndrome.

Authors:  Xiaoshan Zhou; Magnus Johansson; Nicola Solaroli; Björn Rozell; Alf Grandien; Anna Karlsson
Journal:  J Inherit Metab Dis       Date:  2010-05-04       Impact factor: 4.982

Review 2.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

3.  Pearson Syndrome: A Retrospective Cohort Study from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica).

Authors:  Piero Farruggia; Andrea Di Cataldo; Rita M Pinto; Elena Palmisani; Alessandra Macaluso; Laura Lo Valvo; Maria E Cantarini; Assunta Tornesello; Paola Corti; Francesca Fioredda; Stefania Varotto; Baldo Martire; Isabella Moroni; Giuseppe Puccio; Giovanna Russo; Carlo Dufour; Marta Pillon
Journal:  JIMD Rep       Date:  2015-08-04

4.  Haematological abnormalities in mitochondrial disorders.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Singapore Med J       Date:  2015-07       Impact factor: 1.858

5.  mtDNA Deletion in an Iranian Infant with Pearson Marrow Syndrome.

Authors:  Mohammad Taghi Arzanian; Aziz Eghbali; Parvaneh Karimzade; Mitra Ahmadi; Massoud Houshmand; Nima Rezaei
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

Review 6.  Mitochondrial hepatopathy: Respiratory chain disorders- 'breathing in and out of the liver'.

Authors:  Amrit Gopan; Moinak Sen Sarma
Journal:  World J Hepatol       Date:  2021-11-27

Review 7.  Pearson syndrome: a multisystem mitochondrial disease with bone marrow failure.

Authors:  Ayami Yoshimi; Kaori Ishikawa; Charlotte Niemeyer; Sarah C Grünert
Journal:  Orphanet J Rare Dis       Date:  2022-10-17       Impact factor: 4.303

8.  Mitochondrial multiorgan disorder syndrome score generated from definite mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-06       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.